Abstract
SCH-56592 (SCH) is a novel triazole antifungal agent with excellent in vitro activity against Aspergillus. We compared three doses (5, 10, and 25 mg/kg of body weight) of SCH with itraconazole (ITZ; 25 mg/kg) and amphotericin B (AB; 5 mg/kg) in a temporarily neutropenic murine model of disseminated aspergillosis (lungs and kidneys) against one ITZ-susceptible (AF71) and one ITZ-resistant (AF90) isolate of Aspergillus fumigatus. Treatment started 24 h after infection and lasted for 10 days. Dosing regimens for SCH were once daily for 10 days, those for ITZ were three times daily for 2 days and then twice daily for 3 to 10 days, and those for AB were once daily on days 1, 2, 4, and 7. Both isolates killed 90% of control mice. Kidneys and lungs from survivors were cultured on day 11. Against AF71, all three doses of SCH and ITZ yielded a 90 to 100% survival rate and AB yielded 40% survival (P < or = 0.01 to 0.0001 for all treatment groups compared with the controls). All three doses of SCH were superior to AB in cultures of lung and kidney tissue samples (P < or = 0.01 to 0.0002) and SCH at 25 mg/kg was superior to ITZ in cultures of kidneys (P = 0.01). Against AF90, the highest dose of SCH (25 mg/kg) resulted in a 100% survival rate, compared with 60 and 20% survival rates for the groups treated with SCH at 10 and 5 mg/kg, respectively. Treatment with ITZ yielded no survivors. AB therapy achieved a 50% survival rate. SCH at 25 mg/kg (P < 0.001), SCH at 10 mg/kg (P < or = 0.005), and AB (P < 0.05) were superior to ITZ in cultures of lungs and kidneys. There was a correlation between the MICs of SCH and quantitative organ culture results and between the minimum fungicidal concentration of AB with quantitative organ culture results. SCH appears to be a highly effective anti-Aspergillus compound in this model. There appears to be a degree of cross-resistance between itraconazole and SCH.
Full Text
The Full Text of this article is available as a PDF (158.9 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Denning D. W., Hall L., Jackson M., Hollis S. Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. Antimicrob Agents Chemother. 1995 Aug;39(8):1809–1814. doi: 10.1128/aac.39.8.1809. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Denning D. W., Stepan D. E., Blume K. G., Stevens D. A. Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient. J Infect. 1992 Jan;24(1):73–79. doi: 10.1016/0163-4453(92)91066-k. [DOI] [PubMed] [Google Scholar]
- Denning D. W., Stevens D. A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990 Nov-Dec;12(6):1147–1201. doi: 10.1093/clinids/12.6.1147. [DOI] [PubMed] [Google Scholar]
- Denning D. W., Venkateswarlu K., Oakley K. L., Anderson M. J., Manning N. J., Stevens D. A., Warnock D. W., Kelly S. L. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 1997 Jun;41(6):1364–1368. doi: 10.1128/aac.41.6.1364. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Groll A. H., Shah P. M., Mentzel C., Schneider M., Just-Nuebling G., Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996 Jul;33(1):23–32. doi: 10.1016/s0163-4453(96)92700-0. [DOI] [PubMed] [Google Scholar]
- Khoo S. H., Denning D. W. Invasive aspergillosis in patients with AIDS. Clin Infect Dis. 1994 Aug;19 (Suppl 1):S41–S48. doi: 10.1093/clinids/19.supplement_1.s41. [DOI] [PubMed] [Google Scholar]
- Oakley K. L., Moore C. B., Denning D. W. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother. 1997 May;41(5):1124–1126. doi: 10.1128/aac.41.5.1124. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Perfect J. R., Cox G. M., Dodge R. K., Schell W. A. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother. 1996 Aug;40(8):1910–1913. doi: 10.1128/aac.40.8.1910. [DOI] [PMC free article] [PubMed] [Google Scholar]